Paxlovid and Omicron | Alzheimers detection

Paxlovid reduces risks from Omicron variants; blood test for early Alzheimers detection; gut microbes may affect exercise motivation

Having trouble viewing this email? View it as a Web page.

January 10, 2023 Edition

Cell with numerous SARS-CoV-2 virus particles

Paxlovid reduces serious risks from Omicron variants

The antiviral treatment Paxlovid reduced the risk of hospitalization or death from SARS-CoV-2 Omicron variants in older adults by 44%.

Doctor taking a blood sample from a patient

Blood test for early Alzheimers detection

Researchers developed a blood test that could detect Alzheimers disease-promoting compounds in the blood long before symptoms emerged.

White pet mouse running on an exercise wheel in its cage

Gut microbes may affect motivation to exercise

Researchers found a pathway by which gut microbes affect levels of exercise in mice. The findings, if confirmed in humans, suggest strategies to help encourage people to exercise.

Connect with us:

Facebook

RSS Feed

Update Your E-mail Address | Add Subscriptions | Unsubscribe All

If you have questions or problems with the subscription service, please contact subscriberhelp.govdelivery.com. For all other inquiries about NIH programs and activities, please contact Ask NIH. Before writing, please view ourFrequently Asked Questions page, our Health Information page, or Search our website.

This service is provided to you by the National Institutes of Health.
NIHTurning Discovery Into Health

This email was sent to newsletter@newslettercollector.com using GovDelivery Communications Cloud on behalf of: National Institutes of Health (NIH) 9000 Rockville Pike Bethesda MD 20892 301-496-4000 / TTY 301-402-9612

January 10, 2023 Edition

Paxlovid reduces serious risks from Omicron variants

Blood test for early Alzheimers detection

Gut microbes may affect motivation to exercise

Popular Stories:

Connect with us: